17,261 trials
Untreated Childhood Anaplastic Astrocytoma · Untreated Childhood Anaplastic Oligodendroglioma · Untreated Childhood Brain Stem Glioma
Primary: Number of Participants in Phase I Stratum 1A With Dose-limiting Toxicities (DLT) Observed During the First 8 Weeks of Gefitinib Therapy — 2; 0; 1 Participants
Thyroid Neoplasms
Primary: Time to Tumor Progression — 334; 176 days
NSCLC
Primary: Progression-free Survival (PFS) Rate at 3 Months — 28; 12 Participants
Meningococcal Disease
Primary: Geometric Mean Titer of the Meningococcal B Vaccine Against the Different Strains at One Month After First, Second and Third Vaccination. — 2.5; 2.3; 1.8; 33 titer
Parkinson's Disease
Primary: Change From Baseline to Study End Point in the Combined Scores From the UPDRS Subscale II and III Recorded in the Subjects "on" State. — -1; -5 scores on a scale
Type 2 Diabetes Mellitus
Primary: Number of Participants With Adverse Events. — 1; 5; 8; 5 participants
Liver Cirrhosis, Biliary
Primary: DB Phase: Mean Percent Change In Serum Alkaline Phosphatase (ALP) From Baseline To Day 85 — -44.5; -37.6; 0.4 Percent change — p=<0.0001
Carcinoma, Non-Small-Cell Lung
Primary: Phase I: Number of Total Dose-limiting Toxicity (DLT) During Dose Escalation to Determine Maximum Tolerated Dose (MTD) — 0; 0; 1; 0 Dose Limiting Toxicity (DLT)
Post Herpetic Neuralgia · PHN · Neuropathy
Primary: Change in Pain Scores Comparing NP-1 Cream vs. Placebo Cream for Treatment of the Pain of Post Herpetic Neuralgia(PHN)From Baseline to 28 Days. — 2.424; 2.471; 1.877…
Diabetes Mellitus, Type 2
Primary: Change From Baseline in Glycosylated Hemoglobin (Week 12). — 0.06; -0.51; -0.70; -0.76 percentage of Glycosylated Hemoglobin
Dysmenorrhea
Primary: The Primary Efficacy Variable Will be the Time-weighted Average Pain Intensity Over 4 Treatment Days Using the 4 Point Categorical Scale. — 0.91; 0.92 units on a scale
Fibromyalgia
Primary: Mean Change in 3-recording Average of the Subjects Daily Pain Rating on the 0-10 Numeric Pain Intensity Scale. — -3.69; -3.08; -1.97 Scores on a scale
Stress Urinary Incontinence
Primary: Change From Baseline in Opening Urethral Pressure (OUP) at Day 7 — 49.86; 49.86; 49.86; 47.92 centimeter of water (cmH2O) — p=0.4907
Parkinson's Disease
Primary: Tolerability of Isradipine Based on the Number of Participants That Complete the Study — 25 Participants
Acute Lymphoblastic Leukemia · Acute Myelogenous Leukemia · Relapsed Leukemia
Primary: Maximum Tolerated Dose (MTD) in Phase 1 — 0; 0; 0; 0 units on a scale